$241 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 10 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SERA PROGNOSTICS | $26,844,000 | – | 2,416,241 | +100.0% | 11.12% | – | |
| GKOS | Buy | GLAUKOS CORP | $16,872,000 | -42.6% | 350,264 | +1.1% | 6.99% | -24.6% |
| DARE | Buy | DARE BIOSCIENCE INC | $104,000 | +9.5% | 62,065 | +23.2% | 0.04% | +43.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-10-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLAUKOS CORP | 28 | Q3 2023 | 33.0% |
| EIGER BIOPHARMACEUTICALS INC | 24 | Q3 2022 | 17.7% |
| APPLIED GENETIC TECHNOL CORP | 24 | Q3 2022 | 6.7% |
| XENON PHARMACEUTICALS INC | 20 | Q3 2021 | 0.6% |
| CIDARA THERAPEUTICS INC | 19 | Q2 2021 | 4.5% |
| THE REALREAL | 18 | Q3 2023 | 62.6% |
| KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 10.8% |
| DARE BIOSCIENCE INC | 16 | Q3 2023 | 0.3% |
| MACROGENICS INC | 14 | Q1 2020 | 19.2% |
| PMV PHARMACEUTICALS INC | 13 | Q3 2023 | 67.5% |
View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-02-27 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-21 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-04-13 |
| 13F-HR | 2022-01-25 |
| 13F-HR | 2021-10-19 |
View INTERWEST VENTURE MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.